Uncategorized

Next-generation BiDS™ synthetic biology platform to power on-demand, sovereign production of essential medicines and their precursors.

BOULDER, CO, UNITED STATES, July 10, 2026 /EINPresswire.com/ — Khona Scientific, a pioneer of advanced biomanufacturing solutions for complex natural product compounds, today revealed plans to deploy its modular biotechnology platform for production of key starting materials (KSMs) and active pharmaceutical ingredients (APIs) using elementary feedstocks. This trajectory aligns with the growing global need for robust, sovereign pharmaceutical supply chains that are viable alternatives to continued reliance on China and India. The Company will initially pursue two classes of KSMs and APIs – vinca alkaloids and steroid hormones – and plans to expand to six additional compound classes by 2031.

Khona Scientific’s patented BiDS™ biosynthesis system is a versatile platform capable of producing complex, supply-constrained KSMs and APIs using abundant, inexpensive sugars as feedstocks. BiDS™ is akin to a ‘molecular assembly line’ – it (1) enhances yield, quality, throughput, and efficiency, (2) enables scalable, low-cost, regionalized production, and (3) excels where legacy biosynthesis systems struggle. This innovation decouples KSM and API production from vulnerable agricultural inputs, quasi-monopolistic supply chains, and volatile international trade policies.

“Khona Scientific is eager to leverage our technology to solidify KSM and API supply chains,” said Paul Orlady, CEO of Khona Scientific. “There are ongoing and compounding shortages in the global supply of numerous essential medicines. In many cases, these shortages are underpinned by the limited availability of complex natural product KSMs and corresponding APIs. This in turn creates a ceiling in the volume of critical medicines that can be produced and a floor in the cost of production for those medicines. We at Khona Scientific believe that our novel biomanufacturing platform is uniquely capable of addressing key bottlenecks in natural product KSM and API supply chains. This translates to significant market opportunities, particularly in localities like the US and EU where efforts to reshore KSM and API production are gaining momentum.”

Vinca alkaloids are critical medicines in both human and veterinary oncology and are long-standing members of the World Health Organization’s List of Essential Medicines. Despite their vital role in many anticancer treatment regimens, vinca alkaloids are chronically undersupplied. This compromises the availability of treatments for patients and forces physicians to ration care on a daily basis. The most detrimental impact of vinca alkaloid shortages is experienced by pediatric Acute Lymphoblastic Leukemia patients. For these children, the vinca alkaloid vincristine is an essential component of a treatment regimen that offers a nearly 90% cure rate when administered on schedule.

Steroid hormones are the foundation of the burgeoning hormone replacement therapy (HRT) market. HRT has a variety of use cases among women, including for the treatment of menopause symptoms and the prevention of osteoporosis. The regulatory environment for HRT is highly conducive to accelerated market entry. Moreover, there is a lack of reliable steroid hormone supply chains for HRT providers. Capitalizing on these factors, Khona Scientific will operate as a business-to-business supplier of steroid hormones to the growing cohort of compounding pharmacies that formulate HRT to meet patient needs.

By pursuing vinca alkaloids and steroid hormones concurrently, Khona Scientific positions its technology at the confluence of market opportunity, public health importance, and regulatory favorability.

Find this press release on EIN Presswire.

Dr. Gonzalez will bring valuable manufacturing and regulatory expertise to Khona Scientific as it expands production of pharmaceutical key starting materials.

BOULDER, CO, UNITED STATES, May 5, 2026 /EINPresswire.com/ — Khona Scientific Inc., a synthetic biology company advancing biomanufacturing for pharmaceutical key starting materials, is excited to announce the appointment of Michael A. Gonzalez, PhD, to its Board of Directors.

Dr. Gonzalez is Chief Scientific Officer at Bright Path Labs, where he leads scientific strategy for advanced sustainable pharmaceutical manufacturing. With more than 30 years of experience, including 29 years at the U.S. Environmental Protection Agency, he is widely recognized as a global expert in green and sustainable chemistry. His work has focused on translating sustainability principles into measurable, scalable industrial processes for pharmaceuticals, with particular emphasis on continuous manufacturing and data-driven approaches that improve environmental performance and manufacturing resilience.

At Khona Scientific, Dr. Gonzalez will bring deep expertise at the intersection of chemistry, engineering, policy, and pharmaceutical production. His appointment strengthens the company’s strategic guidance as it advances its patented BiDS™ platform to enable efficient biosynthetic production of pharmaceutical key starting materials and to support the development of a more resilient, non-agricultural and domestically-centered supply chain for essential medicine components.

“Michael brings an extraordinary combination of scientific rigor, industrial perspective, and sustainability leadership to Khona Scientific,” said Paul Orlady, Co-Founder and CEO of Khona Scientific. “His career has been defined by turning green chemistry principles into practical manufacturing solutions to overcome pharmaceutical bottlenecks. Michael’s guidance will be invaluable as we look to integrate our products into the pharmaceutical supply chain.”

Dr. Gonzalez’s experience in sustainable chemistry, API production, and continuous manufacturing principles aligns closely with Khona Scientific’s mission to expand access to a wide variety of complex natural key starting materials. His work has emphasized measurable outcomes, process efficiency, and the translation of scientific innovation into industrial practice. These capabilities will support Khona Scientific as it expands its production capabilities and advances partnerships across the pharmaceutical sector.

“I am excited to join Khona Scientific’s Board of Directors at a time when sustainable manufacturing and domestically-centered supply chain resilience are increasingly critical to the future of pharmaceuticals,” said Dr. Gonzalez. “Khona’s platform represents an important opportunity to apply advanced and sustainable biomanufacturing to real-world supply chain issues, and I look forward to supporting the company’s growth and impact.”

Find this press release on EIN Presswire.

BOULDER, CO, UNITED STATES, April 7, 2026 /EINPresswire.com/ — Khona Scientific Inc. is pleased to announce that it has been accepted into the Biopharmaceutical Manufacturing Preparedness (BioMaP) Consortium, a BARDA-supported public-private partnership focused on strengthening U.S. biopharmaceutical manufacturing preparedness. BioMaP’s stated purview includes expanding the domestic biomanufacturing supply chain, increasing manufacturing capacity, and advancing manufacturing technologies that improve responses during public health emergencies.

For Khona Scientific, joining the BioMaP Consortium is a natural next step in its mission to address supply shortages of key starting materials (KSMs). These KSMs are critical for the production of life-saving pharmaceuticals, and the company is leveraging its next-gen biomanufacturing platform to build an alternative supply chain for pharmaceutical KSMs that isn’t bound by the limitations of traditional sources. By helping enable a more diverse and responsive domestic supply chain, the company aims to support the kind of readiness, flexibility, and production continuity that BioMaP was created to encourage across the drug and vaccine manufacturing ecosystem. That ecosystem spans raw materials and consumables, innovative manufacturing technologies, and fill-finish services, reflecting the broad national effort required to improve preparedness.

“Acceptance into the BioMaP Consortium is an exciting milestone for Khona Scientific and a strong validation of the role we believe we can play in the future of U.S. biomanufacturing,” said Paul Orlady, CEO of Khona Scientific. “The BioMaP Consortium brings together organizations who understand that preparedness depends on having trusted domestic capabilities in place before a crisis begins. We’re proud to join this community and contribute to a stronger, more agile, and more resilient manufacturing foundation for essential medicines and public health responses.”

Khona Scientific sees this membership as an opportunity to collaborate with organizations across the BioMaP network that share a commitment to domestic readiness and supply chain resilience. “Khona’s acceptance into BioMaP reflects the growing importance of companies that can help close gaps in the domestic KSM manufacturing landscape,” Orlady added. “We’re looking forward to working alongside consortium members who are committed to making a stronger, more responsive U.S. supply chain.”

About Khona Scientific Inc.

Khona Scientific Inc. is a Colorado-based synthetic biology company focused on creating more robust supply chains for complex natural product compounds, including pharmaceutical Key Starting Materials (KSMs). With its next-gen biomanufacturing platform, the company aims to streamline supply chains currently underserved by conventional agricultural, chemical or biosynthetic production methods.

About the BioMaP Consortium

The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP Consortium) is a BARDA-supported partnership designed to strengthen U.S. preparedness through collaboration with the commercial biopharmaceutical industry. Its current focus areas include industrial base expansion of the biomanufacturing supply chain, biomanufacturing capacity expansion and reservation, and the support of advanced biomanufacturing technologies.

Find this press release on EIN Presswire.

The engagement will explore the use of cellular fermentation to make key starting materials required for pharmaceutical manufacturing.

LONE TREE, CO, UNITED STATES, January 7, 2026 /EINPresswire.com/ — Benuvia Operations, LLC (“Benuvia”), a U.S.-based pharmaceutical development and manufacturing company specializing in regulated and controlled-substance active pharmaceutical ingredients (APIs), today announced the signing of a Letter of Intent (LOI) with Khona Scientific Inc. (“Khona”), a synthetic biotechnology company specializing in the biosynthesis of complex natural compounds.

Under the LOI, the companies intend to collaborate on the evaluation and development of biosynthetic pathways for the commercial production of select controlled-substance APIs. The collaboration combines Benuvia’s expertise in regulated pharmaceutical development, GMP manufacturing, and controlled-substance compliance with Khona’s patented biosynthesis technology and precision fermentation capabilities.

Through this collaboration, the parties will assess scalable, compliant, and sustainable approaches to API production that utilize biosynthetically derived key starting materials. The goal is to support a more resilient and diversified pharmaceutical supply chain for customers domestically and internationally, while maintaining the highest standards of quality, regulatory compliance, and controlled-substance oversight.

“Benuvia brings strong experience in controlled-substance development, regulatory strategy, and GMP execution,” said Paul Orlady, CEO of Khona Scientific. “This LOI establishes a framework to evaluate how our BiDS™ platform can be applied to the development of biosynthetic routes for APIs that require the highest levels of quality, control, and compliance.”

“This Letter of Intent reflects Benuvia’s continued focus on expanding compliant and scalable pathways for the development of highly regulated APIs,” said Terry Novak, CEO of Benuvia Operations. “Khona’s biosynthetic capabilities present a compelling opportunity to evaluate alternative starting-material strategies that may enhance supply-chain resilience while maintaining the stringent quality, regulatory, and controlled-substance requirements expected by our partners and regulators. We look forward to exploring how our respective strengths can be aligned through this collaboration.”

Framework for Technical Evaluation and Future Collaboration

The LOI outlines a framework for technical collaboration, information exchange, and development evaluation activities, with any future definitive agreements subject to regulatory considerations and mutual alignment on technical, commercial, and compliance objectives. Any subsequent manufacturing or commercialization activities would be conducted in accordance with applicable DEA, FDA, and international regulatory requirements.

The collaboration framework was constructed with the support of Madrone Process Development, LLC, which assisted both organizations in aligning technical objectives, regulatory considerations, and development pathways. Madrone helped establish a structured approach for evaluating biosynthetic starting materials within regulated pharmaceutical manufacturing environments.

About Benuvia Operations, LLC

Benuvia Operations, LLC is a U.S.-based pharmaceutical development and manufacturing company specializing in regulated and controlled-substance APIs. The company provides end-to-end capabilities spanning process development, analytical services, regulatory support, and GMP manufacturing. Benuvia supports pharmaceutical and biotechnology partners developing complex small-molecule therapeutics, with particular expertise in cannabinoids, central nervous system (CNS) compounds, and other highly regulated molecules. Learn more at www.benuvia.com.

About Khona Scientific Inc.

Khona Scientific Inc. is a synthetic biology company enabling the biosynthetic production of complex natural compounds. Headquartered in Lone Tree, Colorado, with critical laboratory operations in Boulder, Colorado, Khona leverages its patented BiDS™ biosynthesis platform to integrate enzymatic pathways into cellular “assembly lines,” producing key starting materials for a range of commercial applications. Learn more at www.khonascientific.com.

About Madrone Process Development, LLC

Madrone Process Development, LLC is a Texas-based process development consultancy supporting pharmaceutical, nutraceutical, and food-sector companies in bridging the gap between unregulated and regulated environments. Madrone focuses on optimizing manufacturing processes while supporting regulatory alignment, technology transfer, and scale-up across diverse development and commercialization pathways.

Forward-Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions may identify forward-looking statements. Actual results may differ materially due to risks and uncertainties beyond the companies’ control. These statements are based on information currently available, and the companies assume no obligation to update such statements except as required by applicable law.

Find this press release on EIN Presswire.

LONE TREE, CO, UNITED STATES, November 14, 2024 /EINPresswire.com/ — Khona Scientific Inc., a synthetic biotechnology company and leader in the biosynthetic production of complex compounds, is excited to announce the acquisition of new and expanded laboratory space at Hatchlabs@Wilderness Place in Boulder, Colorado. This strategic move reflects the company’s commitment to enhancing its research and development capabilities and fostering innovation in the bio community.

The new facility, located in the heart of Boulder’s thriving technology and research district, will provide Khona Scientific with state-of-the-art laboratory space and resources to support its growing team of scientists and researchers. The expansion comes as a response to the rapid growth of synthetic biology and demand for complex natural product compounds.

“We are thrilled to announce this significant expansion,” stated Paul Orlady, CEO of Khona Scientific. “This new lab space will not only allow us to increase and accelerate our research capacity but also enhance collaboration among our talented team. We are dedicated to advancing and maturing the capabilities of our patented BiDS™ platform and the facility will be instrumental in achieving such a goal.”

The new lab space will feature advanced equipment and technology designed to support groundbreaking research and development projects. With an emphasis on sustainability and efficiency, the facility will also incorporate eco-friendly practices, aligning with Khona Scientific’s commitment to environmental stewardship.

In addition to expanding its physical footprint, Khona Scientific plans to hire additional scientists and support staff in the coming months and years to further bolster its technology initiatives. This growth will create new job opportunities in the Boulder and greater Denver area, contributing to the local economy and fostering a vibrant scientific community.

Khona Scientific invites members of the community, partners, and stakeholders to visit our Boulder lab facility upon request, by appointment only, to learn more about the Company’s projects and future endeavors.

Find this press release on EIN Presswire.